I believe the market is already valuing NNZ-2591.
The SP rise from the readout of phase 11 success in Phelan McDermid late last year added approximately $1b to Neuren’s market cap. Assuming there was also some value for the market in the molecule prior to that result then the market appears to be valuing each of Trofinetide and NNZ-2591 equally at this time.
I suspect in a few months time NNZ-2591 value in the market will be significantly more.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.14 |
Change
0.290(2.26%) |
Mkt cap ! $1.652B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.92 | $4.547M | 346.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 362 | $13.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 860 | 4 |
View Market Depth
| Last trade - 12.44pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |